192 results about "Amantadine" patented technology

The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and / or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.

The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.

The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and / or the drug-containing coat.

Compositions, and methods of use thereof, are provided for the prevention or treatment of side effects associated with the use of drugs that act as 5HT2 / 5HT3 serotonin receptor antagonists and alpha-2 adrenergic receptor antagonists (5HT2 / 5HT3 antagonist / alpha-2 antagonist). The method involves using dopamine-releasing compounds, such as amantadine, anticonvulsants, such as zonisamide, or dopamine / norepinephrine reuptake inhibitors, such as bupropion, in combination with 5HT2 / 5HT3 antagonist / alpha-2 antagonists, such as mirtazapine, to reduce the excessive daytime drowsiness and / or weight gain associated with 5HT2 / 5HT3 antagonist / alpha-2 antagonist use for the treatment of disorders, such as, depression, schizophrenia, anxiety disorders, sleep-related breathing disorders, insomnia, migraine headache, chronic tension-type headache, hot flashes, lower back pain, neuropathic pain and functional somatic syndromes. Formulations of dopamine-releasing compounds or anticonvulsants with 5HT2 / 5HT3 antagonist / alpha-2 antagonists are provided. In particular embodiments, combination therapy with mirtazapine and zonisamide provides relief from chronic low back pain, while reducing or avoiding side effects associated with monotherapy with mirtazapine or zonisamide.

Disclosed are conjugates in which an aminoadamantane derivative, such as amantadine, memantine, or rimantadine is linked to a therapeutic agent. The conjugate can then be used to target the therapeutic agent to an injured neuron.

Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further contain a pharmaceutical compound in a pharmaceutically effective amount. Non-limiting examples of pharmaceutical compounds include insulin, heparin, bismuth compounds, amantadine and rimantadine.

A disclosed method for simultaneously analyzing and detecting residual veterinary drug compositions in animal tissue comprises: performing homogenate on an animal tissue sample by 50% acetonitrile and ethanol, performing ultrasonic extraction and hexane purifying, and performing further precipitation by acetonitrile and ethanol, concentrating, utilizing UPLC-MS / MS to perform multi-reaction monitoring (MRM) determination under the negative ion mode, and quantifying according to a standard curve and an external standard method, detecting and calculating to obtain the content of 46 residual veterinary drug compositions in animal tissue. The method is applicable to present commonly-used veterinary drugs such as 18 kinds of quinolone drugs, 22 kinds of sulfanilamide drugs, dapsone, phenylethanolamine A, amoxicillin, adamantanamine, rimantadine, ethoxyquin and the like, and is capable of performing one-step simultaneous rapid accurate detection, and the application scope of the method is enlarged.

The invention provides a novel rhodamine fluorescence probe, and belongs to the field of function materials. The novel rhodamine fluorescence probe provided by the invention is characterized in that rhodamine B (RhB) is used as a raw material and is modified by using diamine so as to prepare rhodamine lactam, further the rhodamine lactam reacts with maleic anhydride (MAH) and amantadine so as to obtain the rhodamine fluorescence probe, and the novel rhodamine fluorescence probe contains multiple amido functional groups and carbon-carbon double bonds, wherein the multiple amido functional groups can react with metal ions, and the carbon-carbon double bonds can react with Hg<2+>. After the spiral rhodamine lactam compound is combined with heavy metal particles, the protonation of lactam nitrogen atoms can result in the reduction of the charge density of the nitrogen atoms, thus the cracking of a C-N chemical bond at the spiral center is triggered, so as to generate the fluorescence change and the color change. The obtained rhodamine derivative has relatively good recognition capability on mercury ions and iron ions in a water solution, the detection limit of the obtained rhodamine derivative on the iron ions reaches 8.3ppm, and the detection limit of the obtained rhodamine derivative on the mercury ions reaches 4.7ppm. The prepared rhodamine derivative can serve as the fluorescence probe and is widely applied to the fields such as environmental engineering, detection and the like.

The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In animal models, baculovirus-derived recombinant H5 vaccines were immunogenic and protective, but results in humans were disappointing even when using high doses. Currently, two classes of drugs are available with antiviral activity against influenza viruses: inhibitors of the M2 ion channel, amantadine and rimantadine, and inhibitors of neuraminidase, oseltamivir, and zanamivir. There is paucity of information regarding effectiveness of these drugs in H5N1 infection. These drugs are also well known to have side effects like neurotoxicity. Thus there exists a need to develop alternate therapy for targeting the Avian flu virus (H5N1). The present invention addresses this need in the field.

The present invention generally relates to compositions comprising anesthesia-reversing agents which facilitate or increase the time of awakening or reverse the effects of general anesthesia-induced unconsciousness. In some embodiments, the anesthesia reversing agent can be selected from any or a combination of methylphenidate (MPH), amphetamine, modafinil, amantadine, caffeine, or analogues or derivatives thereof. In some embodiments, compositions comprising at least one or more anesthesia-reversing agents can be used to facilitate awakening from anesthesia without or decreasing occurrence of delirium, and can be used in methods to treat or prevent the symptoms associated with emergence delirium, as well as treat a subject oversedated with general an esthesia. The invention also relates to methods for administering these compositions comprising anesthesia-reversing agents to subjects and for use.

Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir, amantadine, rimantadine, and combinations thereof. The polymer is preferably a water-soluble, biocompatible polymer. Suitable polymers include, but are not limited to, poly(isobutylene-alt-maleic anhydride) (PIBMA), poly(aspartic acid), poly(l-glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof. In another embodiment, the compositions contain a physical mixture of polymer containing one antiviral agent and polymer containing a second antiviral agent. The compositions can be formulated for enteral or parenteral administration. Suitable oral / intranasal dosage forms include, but are not limited to, tablets, capsules, solutions, suspensions, emulsions, syrups, and lozenges. Suitable dosage forms for parenteral administration include, but are not limited to, solutions, suspensions, and emulsions. The compositions described herein are effective at treating a variety of infections, including viral infections such as influenza, while inhibiting or preventing the development of microbial resistance.

The invention discloses a new making method of amantadine, which comprises the following steps: adopting 1, 3-dimethyl adamantane as raw material to do halogenation and Ritter reaction; separating and purifying the make 1-subtituted-amido-3, 5-dimethyl diamantine as intermediate; hydrolyzing the intermediate into diamantine; extracting; obtaining rough product; recrystallizing the rough product to obtain the fined product; fitting for industrial manufacturing.

The invention discloses an adamantyl quaternary ammonium salt and a preparation method thereof. The structural formula of the adamantyl quaternary ammonium salt is shown as right formula, wherein R represents phenmethyl or alkyl containing 1 to 18 carbon atoms; and X represents Cl, Br or I. The preparation method of the adamantyl quaternary ammonium salt adopts amantadine as a material and adopts two-step reaction as follows: adopting amantadine to synthesize adamantyl dimethyl-tert-amine and then synthesizing the adamantyl quaternary ammonium salt through quaterisation of the adamantyl dimethyl-tert-amine. The invention has easy operation, mild reaction process, high yield and purity and low product eco-toxicity. The cation surface active agent of the adamantyl quaternary ammonium salt can be potentially applied to high and new technology fields of micro-electronics, biomedicine, pharmacy, nanometer material and the like.

The invention provides a method for amplifying colloidal gold immunochromatographic colorimetric signal intensity. The method comprises the following steps: closing a gold-labelled antibody by using amantadine marked bovine serum albumin to obtain a gold-labelled antibody I; synthesizing colloidal gold nanoparticles by using beta-cyclodextrin to obtain a beta-cyclodextrin coated colloidal gold solution; after adding a to-be-tested sample into a system which executes double-antibody sandwich colloidal gold immunochromatography by using the gold-labelled antibody I, adding the beta-cyclodextrincoated colloidal gold solution; and adding a mixed solution of 5,10,15,20-tetra(4-carboxyl phenyl)porphyrin and the beta-cyclodextrin coated colloidal gold solution into the system repeatedly for manytimes. According to the method, net-shaped nano-gold is formed by utilizing supermolecular self-assembling principle mediation and circular signal amplification is realized, so that the developing intensity of the god nanoparticles on a detection line and a quality control line is greatly improved and the aim of performing on-site rapid detection on a target detection object with ultralow concentration can be fulfilled. The invention also provides a high-sensitivity kit applied to colloidal gold immunochromatography.

The invention discloses a hybridoma cell strain secreting an anti-amantadine monoclonal antibody and application of the hybridoma cell strain. The name of the hybridoma cell strain is hybridoma cell strain 7G4.3, and the collection number is CCTCC No. C2014169. The hybridoma cell strain is obtained by immunizing a mouse with a self-designed amantadine artificial antigen and using spleen cells of the immunized mouse, the anti-amantadine monoclonal antibody secreted by the hybridoma cell strain has high titer and strong specificity, and can be used for fast and accurate immunodetection and immunoassay of amantadine.

An application of the polyose sulfate (marinofloridpolyose sulfate, alpha-D-(1-6)-glucosan sulfate, or porphyran sulfate) in preparing the medicines for preventing and treating viral influenza A or B is disclosed.

The invention belongs to the technical field of poultry product detection and relates to a combined detection method of amantadine, rimantadine, ribavirin and moroxydine residues in eggs. The method comprises the following steps: carrying out low temperature repetitive freeze-thawing on a sample, adding a formic acid-methanol solution, mixing, centrifuging, taking a supernatant for standby, adding water saturated n-hexane, mixing, carrying out ultrasonic treatment, centrifuging to remove n-hexane floccules on the upper layer with an extracting solution left at the lower layer, purifying with a cation exchange solid-phase extraction column, measuring by a liquid chromatography-tandem mass spectrometer provided with an ESI source, and carrying out accurate qualitative and quantitative analysis on residues of the four antiviral drugs in eggs. The method provided by the invention has high specificity, can accurately and simultaneously measure residual quantity of amantadine, rimantadine, ribavirin and moroxydine without pollution, has high sensitivity, and provides technical support for guaranteeing quality safety of eggs.

The invention provides a detection kit of acetyl amantadine for predicting tumors. The kit comprises a carrier coated with an acetyl amantadine-resisting monoclonal antibody A and an acetyl amantadine-resisting monoclonal antibody B with a marker. The kit detects the acetyl amantadine in a sample on the basis of an immunological principle. The kit is used for detecting the acetyl amantadine for predicting the tumors, has the advantages of simplicity, fastness, high sensitivity and low cost and is easy to popularize and use on a large scale. In addition, the detection kit jointly applies an immunological method for detecting the acetyl amantadine and a biochemical method for detecting C-reactive protein (CRP) and troponin so as to eliminate false positive interference to tumor prediction due to diseases such as internal inflammation and myocardial ischemia and make the specificity of a method for early predicting cancers by detecting the acetyl amantadine higher.

The invention relates to an amantadine nitrate compound with a neuroprotective effect, and preparation therefor and medical application thereof. The compound has a structure of a general formula (I) as shown in the specification, has multimechanisms, comprises NMDA receptor inhibition, NO releasing and inhibition of inward flow of calcium ions, and has a good protection effect on cells, particularly on neurons. The compound can be used for preparing drugs with a cytoprotection effect, and the drugs are used for preventing or treating diseases related to increasing of NMDA receptors, calcium ions in cells and the like, such as diseases related to neurodegeneration including senile dementia, parkinson's disease, brain stroke, glaucoma and the like, diseases related to a cardio-cerebrovascular system including parkinsonism combined with cerebral arteriosclerosis, and respiratory tract infectivity caused by influenza viruses.

A process for synthesizing Memantine characterized in that, the Memantine is prepared from bromization dimethyl Amantadine through amination reaction with carbamide and acidification reaction with chlorhydric acid.

The application provides a kit for detecting drug residues in meat. The kit contains a hybrid cation exchange solid-phase extraction column, an extract of adamantanamine, quinolones and sulfanilamide medicines, a first leacheate, a second leacheate, an eluate and a reconstitution fluid. The invention also provides a drug residue detection method by the use of the kit. Pretreatment methods of the above three medicines are integrated to design a kit for simultaneous pretreatment of drug residues of adamantanamine, quinolones and sulfanilamide medicines. The kit can be used for pretreating the above three medicines simultaneously. After pretreatment, chromatography or mass spectrometry of a sample can be carried out by a conventional technology.

Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

The invention discloses an amantadine artificial hapten and an artificial antigen as well as a preparation method and application of the amantadine artificial hapten and the artificial antigen. The molecular structural formula of the amantadine artificial hapten is as shown in the formula (I), and the molecular structural formula of the amantadine artificial antigen is as shown in the formula (II). The application is to utilize the amantadine artificial antigen to prepare an amantadine antibody. The amantadine artificial hapten disclosed by the invention retains the feature structure of amantadine to the largest extent, comprises active groups capable of being linked and coupled with carrier protein as an antigen determinant; the prepared and obtained amantadine artificial antigen can be immunized to obtain the amantadine antibody with high affinity, high sensitivity and high specificity; the titer of immune serum obtained by immunizing a New Zealand white rabbit is up to 1:70000; the amantadine artificial hapten and the artificial antigen can be used for quick and accurate immunodetection and immunoassay to amantadine.

The present invention discloses a synthetic method of N-rimantadine. Adamantanamine hydrochloride or admantadine is dissolved in water and / or water-soluble organic solvent, and then, formalin is added to make methylenation reaction; after the methylenation reaction is end, generated admantadine amine-methylene are dissolved into the ater-soluble organic solvent after being extracted, separated and washed, and sodium borohydride is added to make reduction reaction to obtain a N- rimantadine crude product by separation after the reduction reaction; and the N- rimantadine crude product is purified. A synthetic method of organic compound replaced by single methyl of hydrogen on admantadine with high selection and high generation rate is obtained by the reaction provided by the present invention. The reaction conditions are worm, and a noble metal catalyst and a tetrahydro lithium aluminum reducing agent are avoided to use.

The present invention belongs to the field of chemically synthesized medicine and its preparation process. The medicine of the present invention is synthesized with amantadine, moroxydine, 5-Fu (5-Fc), isoniazid and other clinical medicine and polyoxometallate, and through self-assembling. The said polyoxometallate includes heteropoly acid salts of Keggin type with chemical expression XM12O40n-, Dowson type X2M18O62n- and of chemical expression LnW10O36n-. The combined use of said medicines and polyoxometallate has obvious curative effect on intractable streptococcus pneumoniae infection.

This invention concerns adamantanamines (e.g. memantine, amantadine, and rimantadine) and neramexane salts of thiomolybdic and thiotungstic acids, including their preparation and pharmaceutical compositions, as dual acting drugs. These salts are used to treat or potentially arrest the neurodegenerative pathophysiology, clinical signs and symptoms of dementia of the Alzheimer's type, Parkinson's, Huntington's, AIDS-related dementia and Schizophrenia and its cognitive deficits. Additional uses of these derivatives include antiviral activity. The novel compositions of the present invention appear particularly useful in enhancing the therapeutic benefits of copper-sequestering tetrathiomolybdates in treating elevated copper-induced toxicities in neurologically presenting Wilson's disease, and in treating diseases of the inflammatory etiology and abnormal copper biochemistry, such as tumor angiogenesis, liver cirrhosis, hepatitis, pulmonary fibrosis and other fibrotic diseases, cardiovascular disease, cerebral ischemia, renal anemia, rheumatoid arthritis, diabetes, obesity, gastrointestinal disorders, and eye diseases such as glaucoma, proliferative diabetic retinopathy, and age related macular degeneration. These compounds have excellent stability and aqueous solubility for good oral bioavailability.

The invention discloses an antigen, an antibody and an enzyme-linked immunosorbent assay (ELISA) kit of amantadine. Firstly, an amantadine hapten is prepared, wherein the molecular structural formulaof the amantadine hapten is as shown in formula (I) (The formula is shown in the description.); then, the amantadine hapten is coupled with carrier protein to obtain an artificial antigen; and then, amonoclonal antibody of amantadine is obtained through a hybridoma technique, thereby establishing a competitive ELISA method and kit according to the monoclonal antibody of amantadine. The ELISA kitof amantadine, disclosed by the invention, can be used for detecting the content of amantadine in an animal tissue sample, the detection limit is 0.10mu g / kg, IC50 is 0.79mu g / L, and the linear detection range is 0-16.2mu g / L; and the method is simple, convenient and quick, is low in cost, high in sensitivity and highstrong in specificity, and is suitable for on-site quick detection.